Truist raised the firm’s price target on Cigna to $380 from $365 and keeps a Buy rating on the shares. The firm is citing the company’s “strong” Q4 results, with top and bottom-line beats, better medical care ratio, solid growth across segments, and FY24 EPS guidance that was ahead of estimates, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CI:
- The Cigna Group Announces Commencement of Tender Offers for up to $2.25 Billion in Aggregate Principal Amount of Outstanding Notes
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Cigna (NYSE:CI) Surges on Q4 Beat, Raises Dividend By 14%
- Early notable gainers among liquid option names on February 2nd
- Options Volatility and Implied Earnings Moves Today, February 02, 2024